These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16277710)

  • 1. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
    de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vroom MB; Meijers JC; Büller HR; Levi M
    Crit Care; 2005 Oct; 9(5):R490-7. PubMed ID: 16277710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
    Derhaschnig U; Reiter R; Knöbl P; Baumgartner M; Keen P; Jilma B
    Blood; 2003 Sep; 102(6):2093-8. PubMed ID: 12750166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated protein C attenuates endothelial injury and inhibits procoagulant microparticles release in baboon heatstroke.
    Bouchama A; Kunzelmann C; Dehbi M; Kwaasi A; Eldali A; Zobairi F; Freyssinet JM; de Prost D
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1318-25. PubMed ID: 18451327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel treatment for severe sepsis: recombinant human protein C (RHAPC)].
    Uszyiński W; Uszyński M; Lisiecki A
    Ginekol Pol; 2005 Nov; 76(11):913-20. PubMed ID: 16566369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
    Gullo A; Iscra F; Di Capua G; Berlot G; Lucangelo U; Peratoner A; Fasiolo S; Viviani M; Consales C; Zicari A
    Minerva Anestesiol; 2005 Dec; 71(12):785-801. PubMed ID: 16288186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
    Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B
    Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
    Bernard GR; Ely EW; Wright TJ; Fraiz J; Stasek JE; Russell JA; Mayers I; Rosenfeld BA; Morris PE; Yan SB; Helterbrand JD
    Crit Care Med; 2001 Nov; 29(11):2051-9. PubMed ID: 11700394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.
    Spiel AO; Firbas C; Mayr FB; Leitner JM; Schmidt B; Knöbl P; Varadi K; Jilma B
    Thromb Haemost; 2005 Dec; 94(6):1148-55. PubMed ID: 16411386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
    Cvirn G; Gallistl S; Koestenberger M; Baier K; Fritsch P; Greilberger J; Jürgens G; Muntean W
    Thromb Haemost; 2004 May; 91(5):912-8. PubMed ID: 15116251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis.
    Brueckmann M; Hoffmann U; Dvortsak E; Lang S; Kaden JJ; Borggrefe M; Haase KK
    Inflamm Res; 2004 Oct; 53(10):528-33. PubMed ID: 15597147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M; Cvirn G; Gallistl S; Muntean W
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human activated protein C: current insights into its mechanism of action.
    Levi M; van der Poll T
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S3. PubMed ID: 18269690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
    Maybauer MO; Maybauer DM; Fraser JF; Traber LD; Westphal M; Enkhbaatar P; Cox RA; Huda R; Hawkins HK; Morita N; Murakami K; Mizutani A; Herndon DN; Traber DL
    Crit Care Med; 2006 Sep; 34(9):2432-8. PubMed ID: 16810106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
    Robriquet L; Collet F; Tournoys A; Prangère T; Nevière R; Fourrier F; Guery BP
    Respir Res; 2006 Mar; 7(1):41. PubMed ID: 16553944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.